|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 130.86 USD | +0.40% |
|
-0.64% | +6.62% |
| 07-23 | Leerink Partners Adjusts Gilead Sciences Price Target to $126 From $127, Maintains Market Perform Rating | MT |
| 07-22 | What Bundibugyo Ebola vaccines and treatments are under development | RE |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Neutral | Neutral |
| Resistance | 136.36 | 155.8 | 154.98 |
| Spread/Res. | -4.03% | -16.01% | -15.56% |
| Spread/Supp. | +2.85% | +7.72% | +16.74% |
| Support | 127.23 | 121.48 | 112.1 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- GILD Stock
- Charts Gilead Sciences, Inc.
Select your edition
All financial news and data tailored to specific country editions
